NSE: MANKIND · 23 October 2026
- Mankind Pharma Limited shares declined -2.77% on Thursday, closing at ₹2,212.60 after trading within a daily range of ₹2,196.10 and ₹2,289.60.
- Mankind Pharma announced through its subsidiary Mankind Pharma Netherlands B.V. that it has entered into a definitive agreement to acquire a 70% stake in Belgium-incorporated biotechnology firm Armed Cell Therapeutics B.V. The investment involves deploying up to EUR 48 million in installments to support next-generation CAR-T cell therapies targeting cancers such as non-Hodgkin lymphoma and small cell lung cancer. Key biotech veterans including Dr. Paul Stoffels and Dr. John Mellors lead the target's R&D activities.
- Trading volume was 1.12 times the 20-day average daily volume.
Why is Mankind Pharma share price falling on 23 October 2026?
Mankind Pharma Limited shares declined -2.77% on Thursday, closing at ₹2,212.60 after trading within a daily range of ₹2,196.10 and ₹2,289.60.
The broader market and sector benchmarks also finished in negative territory, with the Nifty falling -0.39% and the Nifty Pharma sector index declining -1.04%. Mankind Pharma's retreat fits within a softer multi-session trend, as the stock has recorded a 5-day return of -5.75% and a 20-day return of -10.24%.
While the company recently announced an upcoming analyst conference call scheduled for October 22, 2026, to discuss its financial results for the quarter and half-year ended September 30, 2026, no single operational announcement was explicitly linked to today's downward price action. The session's pullback appears consistent with broader sector weakness and ongoing consolidation ahead of its upcoming earnings reporting date.
6.79 lakh shares traded by 23 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 6.04 lakh shares (1.12 times). The five-day average daily volume was 7.32 lakh shares. Separately, the NSE report for 23 October 2026 showed 4.19 lakh shares delivered, representing 61.65% of that day’s traded volume. The same report recorded 25,717 trades.
The stock declined alongside broader pharmaceutical sector softness and negative multi-session momentum, while trading slightly above its 20-day average volume without any direct negative same-day corporate trigger.
Latest Company Developments
Mankind Pharma announced through its subsidiary Mankind Pharma Netherlands B.V. that it has entered into a definitive agreement to acquire a 70% stake in Belgium-incorporated biotechnology firm Armed Cell Therapeutics B.V. The investment involves deploying up to EUR 48 million in installments to support next-generation CAR-T cell therapies targeting cancers such as non-Hodgkin lymphoma and small cell lung cancer. Key biotech veterans including Dr. Paul Stoffels and Dr. John Mellors lead the target's R&D activities.
This strategic acquisition marks Mankind Pharma's entry into next-generation CAR-T therapies as part of its long-term ambition to build a global innovation-led pharmaceutical business.
The company disclosed that NSE Sustainability Ratings and Analytics Limited independently assigned an Environmental, Social, and Governance rating of 71 to Mankind Pharma for fiscal year 2026. The rating was generated using publicly available information without a direct company engagement.
An independent ESG rating provides institutional investors with a formal benchmark regarding the company's sustainability practices and non-financial governance standards.
Following an earlier technical issue with conference access links on October 22, 2026, Mankind Pharma re-submitted its intimation regarding the rescheduled analyst and institutional investor conference call. The call supports discussions surrounding the upcoming financial results for the quarter and half year ended September 30, 2026.
Ensures transparent communication channels with analysts and institutional investors prior to the official release of financial performance metrics.
Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 11.31% on 30 September 2026. This compares with 10.87% on 30 June 2026, a change of +0.44 percentage points.
The filing reported 36 MF/UTI holders.
What to Watch Next
- Upcoming financial results and earnings conference call for the quarter and half year ended September 30, 2026
- Execution milestones regarding the majority stake acquisition in Armed Cell Therapeutics
- Delivery volume trends relative to the 20-day average volume of 1.12x
- Performance trajectory of the Nifty Pharma sector benchmark
Other Dated Coverage
- Mankind Pharma in Focus After Acquiring Majority Stake in Armed Cell Therapeutics | 16 October 2026 — 16 October 2026
- Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.47% | 14 October 2026 — 14 October 2026
- Why Mankind Pharma Shares Fell 2.21% Today: Sector Weakness & Context | 5 October 2026 — 5 October 2026
More Mankind Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Mankind Pharma company news?
Mankind Pharma announced through its subsidiary Mankind Pharma Netherlands B.V. that it has entered into a definitive agreement to acquire a 70% stake in Belgium-incorporated biotechnology firm Armed Cell Therapeutics B.V. The investment involves deploying up to EUR 48 million in installments to support next-generation CAR-T cell therapies targeting cancers such as non-Hodgkin lymphoma and small cell lung cancer. Key biotech veterans including Dr. Paul Stoffels and Dr. John Mellors lead the target's R&D activities.
How strong was Mankind Pharma’s trading volume?
6.79 lakh shares traded, 1.12 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.